iTeos Therapeutics Stock Price, News & Analysis (NASDAQ:ITOS) $9.90 +0.54 (+5.77%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$8.95▼$9.9150-Day Range$8.58▼$11.5152-Week Range$8.20▼$23.00Volume341,252 shsAverage Volume357,686 shsMarket Capitalization$354.22 millionP/E RatioN/ADividend YieldN/APrice Target$35.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media iTeos Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside256.9% Upside$35.33 Price TargetShort InterestHealthy5.57% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.92Based on 4 Articles This WeekInsider TradingAcquiring Shares$41,850 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($3.07) to ($5.43) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.58 out of 5 starsMedical Sector124th out of 949 stocksBiological Products, Except Diagnostic Industry16th out of 161 stocks 3.5 Analyst's Opinion Consensus RatingiTeos Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $35.33, iTeos Therapeutics has a forecasted upside of 256.9% from its current price of $9.90.Amount of Analyst CoverageiTeos Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.57% of the float of iTeos Therapeutics has been sold short.Short Interest Ratio / Days to CoveriTeos Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in iTeos Therapeutics has recently decreased by 9.14%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldiTeos Therapeutics does not currently pay a dividend.Dividend GrowthiTeos Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ITOS. Previous Next 3.3 News and Social Media Coverage News SentimentiTeos Therapeutics has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for iTeos Therapeutics this week, compared to 1 article on an average week.Search Interest18 people have searched for ITOS on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added iTeos Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, iTeos Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $41,850.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders10.20% of the stock of iTeos Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.16% of the stock of iTeos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for iTeos Therapeutics are expected to decrease in the coming year, from ($3.07) to ($5.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of iTeos Therapeutics is -5.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of iTeos Therapeutics is -5.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioiTeos Therapeutics has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About iTeos Therapeutics Stock (NASDAQ:ITOS)Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.Read More ITOS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ITOS Stock News HeadlinesNovember 29, 2023 | fool.comiTeos Therapeutics (NASDAQ: ITOS)November 27, 2023 | finance.yahoo.comDoes iTeos Therapeutics, Inc. (ITOS) Have the Potential to Rally 283.59% as Wall Street Analysts Expect?December 1, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 21, 2023 | finance.yahoo.comiTeos to Present at the Piper Sandler 35th Annual Healthcare ConferenceNovember 14, 2023 | markets.businessinsider.comiTeos Therapeutics’ Anticipated Growth and Clinical Updates Drive Buy Rating: An Analyst’s PerspectiveNovember 13, 2023 | finance.yahoo.comHere's Why iTeos Therapeutics, Inc. (ITOS) Could be Great Choice for a Bottom FisherNovember 10, 2023 | finance.yahoo.comWall Street Analysts Predict a 304.26% Upside in iTeos Therapeutics, Inc. (ITOS): Here's What You Should KnowNovember 10, 2023 | finance.yahoo.comWall Street Analysts Predict a 304.26% Upside in iTeos Therapeutics, Inc. (ITOS): Here's What You Should KnowDecember 1, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 9, 2023 | markets.businessinsider.comPositive Financial Results and Promising Cancer Treatment Programs Underpin Buy Rating for iTeos TherapeuticsNovember 7, 2023 | finance.yahoo.comiTeos Reports Third Quarter 2023 Financial Results and Provides Business UpdatesOctober 31, 2023 | finance.yahoo.comViridian Therapeutics, Inc. (VRDN) Stock Jumps 5.2%: Will It Continue to Soar?October 19, 2023 | msn.comWedbush Reiterates ITeos Therapeutics (ITOS) Outperform RecommendationOctober 16, 2023 | finance.yahoo.comiTeos Therapeutics, Inc. (ITOS) Stock Jumps 5.4%: Will It Continue to Soar?October 12, 2023 | finanznachrichten.deS&P Dow Jones Indices: NCR Atleos Set to Join S&P SmallCap 600September 6, 2023 | finance.yahoo.comiTeos to Participate in Upcoming Investor ConferencesAugust 27, 2023 | finance.yahoo.comBOXER CAPITAL, LLC Reduces Stake in ITeos Therapeutics IncAugust 25, 2023 | seekingalpha.comiTeos Therapeutics And The TIGIT Ticket To Cancer's DownfallAugust 23, 2023 | bizjournals.comWatertown biotech shares spike after accidental data publication at RocheAugust 23, 2023 | markets.businessinsider.comWhy ITeos Therapeutics (ITOS) Stock Is Moving HigherAugust 23, 2023 | finance.yahoo.comWhy Roche's Accidental Cancer Update Boosted Iteos 41% And Arcus 28%August 9, 2023 | msn.comHC Wainwright & Co. Maintains ITeos Therapeutics (ITOS) Buy RecommendationAugust 9, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on iTeos Therapeutics (ITOS)August 8, 2023 | finanznachrichten.deiTeos Therapeutics Inc.: iTeos Reports Second Quarter 2023 Financial Results and Provides Business UpdatesAugust 8, 2023 | finance.yahoo.comiTeos Reports Second Quarter 2023 Financial Results and Provides Business UpdatesJune 4, 2023 | seekingalpha.comiTeos Therapeutics: Trading Under Cash ValueMay 13, 2023 | finance.yahoo.comBroker Revenue Forecasts For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Are Surging HigherSee More Headlines Receive ITOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iTeos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today12/01/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/20/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ITOS CUSIPN/A CIK1808865 Webwww.iteostherapeutics.com Phone339-217-0161FaxN/AEmployees125Year FoundedN/APrice Target and Rating Average Stock Price Target$35.33 High Stock Price Target$44.00 Low Stock Price Target$29.00 Potential Upside/Downside+256.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$96.65 million Net Margins9.02% Pretax Margin-87.36% Return on Equity-9.72% Return on Assets-8.61% Debt Debt-to-Equity RatioN/A Current Ratio21.94 Quick Ratio21.94 Sales & Book Value Annual Sales$267.63 million Price / Sales1.32 Cash Flow$2.75 per share Price / Cash Flow3.60 Book Value$16.72 per share Price / Book0.59Miscellaneous Outstanding Shares35,780,000Free Float32,135,000Market Cap$354.22 million OptionableNot Optionable Beta1.23 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Michel Detheux Ph.D. (Age 57)President, CEO & Director Comp: $922.38kMr. Matthew A. Call M.B.A. (Age 50)Chief Operating Officer Comp: $638.55kMr. Matthew Gall (Age 46)Chief Financial Officer Comp: $628.45kDr. Yvonne McGrath Ph.D. (Age 49)Chief Scientific Officer Mr. Ryan BakerHead of Investor RelationsMs. Adi OsovskyVP & Head of LegalMr. Phillipe BrantegemVice-President of Human ResourcesMore ExecutivesKey CompetitorsTaysha Gene TherapiesNASDAQ:TSHAFusion PharmaceuticalsNASDAQ:FUSNMeiraGTxNASDAQ:MGTXCullinan OncologyNASDAQ:CGEMOrchard TherapeuticsNASDAQ:ORTXView All CompetitorsInsiders & InstitutionsAmerican Century Companies Inc.Sold 19,491 shares on 11/30/2023Ownership: 0.144%Deutsche Bank AGBought 2,552 shares on 11/24/2023Ownership: 0.069%Public Sector Pension Investment BoardSold 11,074 shares on 11/22/2023Ownership: 0.091%Comerica BankBought 12,243 shares on 11/21/2023Ownership: 0.034%Jacobs Levy Equity Management Inc.Sold 30,668 shares on 11/17/2023Ownership: 1.285%View All Insider TransactionsView All Institutional Transactions ITOS Stock Analysis - Frequently Asked Questions Should I buy or sell iTeos Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for iTeos Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ITOS shares. View ITOS analyst ratings or view top-rated stocks. What is iTeos Therapeutics' stock price target for 2024? 3 equities research analysts have issued 12-month price objectives for iTeos Therapeutics' shares. Their ITOS share price targets range from $29.00 to $44.00. On average, they anticipate the company's stock price to reach $35.33 in the next twelve months. This suggests a possible upside of 256.9% from the stock's current price. View analysts price targets for ITOS or view top-rated stocks among Wall Street analysts. How have ITOS shares performed in 2023? iTeos Therapeutics' stock was trading at $19.53 at the beginning of 2023. Since then, ITOS stock has decreased by 49.3% and is now trading at $9.90. View the best growth stocks for 2023 here. Are investors shorting iTeos Therapeutics? iTeos Therapeutics saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 1,590,000 shares, a decrease of 9.1% from the October 31st total of 1,750,000 shares. Based on an average trading volume of 431,100 shares, the short-interest ratio is presently 3.7 days. Currently, 5.6% of the company's shares are sold short. View iTeos Therapeutics' Short Interest. When is iTeos Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024. View our ITOS earnings forecast. How were iTeos Therapeutics' earnings last quarter? iTeos Therapeutics, Inc. (NASDAQ:ITOS) posted its earnings results on Tuesday, November, 7th. The company reported ($0.90) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.20) by $0.30. iTeos Therapeutics had a net margin of 9.02% and a negative trailing twelve-month return on equity of 9.72%. What ETFs hold iTeos Therapeutics' stock? ETFs with the largest weight of iTeos Therapeutics (NASDAQ:ITOS) stock in their portfolio include Invesco S&P SmallCap 600 Pure Growth ETF (RZG) and Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC). What other stocks do shareholders of iTeos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other iTeos Therapeutics investors own include Advanced Micro Devices (AMD), GW Pharmaceuticals (GWPH), Trevena (TRVN), Blink Charging (BLNK), Chegg (CHGG), Centene (CNC), Datadog (DDOG), Global Blood Therapeutics (GBT) and Genocea Biosciences (GNCA). When did iTeos Therapeutics IPO? (ITOS) raised $151 million in an IPO on Friday, July 24th 2020. The company issued 8,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are iTeos Therapeutics' major shareholders? iTeos Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include 683 Capital Management LLC (2.26%), Deerfield Management Company L.P. Series C (2.02%), Jacobs Levy Equity Management Inc. (1.28%), Barclays PLC (0.90%), Bank of New York Mellon Corp (0.78%) and Northern Trust Corp (0.77%). Insiders that own company stock include Aaron I Davis, Ansbert Gadicke, Bioventures 2014 LP Mpm, Bioventures 2018 LP Mpm, Boxer Capital, Llc, David Hallal, Detlev Biniszkiewicz, Joanne Jenkins Lager, Les B Korsh, Matthew Gall, Michel Detheux and Yvonne Mcgrath. View institutional ownership trends. How do I buy shares of iTeos Therapeutics? Shares of ITOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ITOS) was last updated on 12/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iTeos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.